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	 The	degradation	of	eprosartan	was	evaluated	under	 ICH/WHO	prescribed	stress	conditions.
The	drug	degraded	to	only	one	product	under	photo	alkali	condition,	whereas	it	was	stable	to
conditions	 of	 hydrolysis,	 oxidation	 and	 thermal	 stress.	 The	 drug	 and	 its	 co‐eluting	 product
were	well	separated	on	RP‐HPLC	 in	a	gradient	mode.	Subsequently,	LC‐MS/TOF	and	on‐line
H/D	 exchange	 studies	 were	 performed	 on	 both	 of	 them.	 The	 two	 showed	 same	molecular
mass,	 similar	 fragment	 ions	 and	 even	 the	 same	 number	 of	 labile	 hydrogens	 indicating	 the
product	to	be	an	isomer	of	the	drug.	To	confirm	the	same,	1H	and	COSY	LC‐NMR	studies	were
carried	out	by	using	an	enriched	sample.	Distinguishing	behaviour	of	chemical	shifts	proved
the	product	to	be	(Z)‐4‐((2‐butyl‐5‐(2‐carboxy‐3‐(thiophen‐2‐yl)prop‐1‐enyl)‐1H‐imidazol‐1‐
yl)methyl)benzoic	 acid.	 The	 structure	 was	 further	 supported	 by	 differential	 LC‐MS	 ion
intensities	of	the	drug	and	the	product.	
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1.	Introduction	
	
As	 per	 the	 International	 Conference	 on	 Harmonization	
(ICH)	 [1]	 and	 the	 World	 Health	 Organization	 (WHO)	 [2]	
stability	 test	 guidelines,	 stress	 studies	 and	 identification/	
characterization	 of	 degradation	 product(s)	 are	mandatory	 for	
new	 and	 existing	 drug	 molecules,	 respectively.	 Generally	
during	 stress	 and	 stability	 studies,	 the	 degradation	 products	
are	 generated	 in	 small	 quantities.	 So	 their	 characterization	
turns	out	to	be	a	cumbersome	process,	when	the	conventional	
approach	 of	 isolation	 and	 spectral	 analysis	 is	 followed.	
Therefore,	 advanced	 hyphenated	 techniques,	 like	 LC‐MS	 and	
LC‐NMR,	are	being	extensively	explored	for	this	purpose	since	
the	last	few	years	[3‐8].	
Eprosartan	 is	an	angiotensin	 II	 receptor	antagonist,	which	
is	used	in	the	treatment	of	hypertension	[9].	Although,	the	drug	
was	approved	by	US‐FDA	in	1997	[10],	only	scant	information	
on	its	degradation	behaviour	is	known	[11].	There	is	no	report	
involving	stress	testing	on	the	drug.	Most	of	the	literature	texts	
cover	 development	 of	 HPLC	 and	 LC‐MS	 methods	 for	 the	
determination	of	drug	in	different	matrices	[11‐13].	Therefore,	
an	endeavour	of	the	present	study	was	to:	(i)	degrade	the	drug	
under	 conditions	 of	 hydrolysis,	 oxidation,	 photolysis	 and	
thermal	stress,	as	prescribed	by	ICH	and	WHO,	(ii)	separate	the	
drug	 and	 the	 degradation	 product(s)	 on	 a	 LC	 column,	 (iii)	
obtain	 necessary	 spectral	 information	 for	 the	 generated	
degradation	 product(s)	 using	 LC‐MS	 and	 LC‐NMR,	 and	 (iv)	
characterize	 the	 degradation	 product(s)	 formed	 from	 the	
available	data.	
	
2.	Experimental	
	
2.1.	Drug	and	reagents	
	
Pure	 eprosartan	 was	 obtained	 as	 gratis	 sample	 from	
Ranbaxy	 Research	 Laboratories	 (Gurgaon,	 India).	 Analytical	
reagent	 (AR)	 grade	 sodium	hydroxide	 (NaOH)	was	purchased	
from	 Ranbaxy	 Laboratories	 (S.A.S.	 Nagar,	 India),	 hydrochloric	
acid	 (HCl)	 from	 LOBA	 Chemie	 Pvt.	 Ltd.	 (Mumbai,	 India)	 and	
hydrogen	 peroxide	 (H2O2)	 from	 s.d.	 fine‐chem	 Ltd.	 (Boisar,	
India).	 Buffer	 salts	 and	 all	 other	 chemicals	 were	 also	 of	 AR	
grade	and	bought	from	local	suppliers.	HPLC	grade	acetonitrile	
(ACN)	 and	methanol	 (MeOH)	were	 procured	 from	 J.	 T.	 Baker	
(Phillipsburg,	NJ,	USA).	NMR	grade	ACN	and	deuterated	water	
(D2O)	 of	 99.9%	 purity	 were	 obtained	 from	 Riedel‐de	 Haen	
(Seelze,	 Germany)	 and	 Aldrich	 (California,	 Missouri,	 USA),	
respectively.	 ES	 Tuning	 Mix	 solution	 (Agilent	 Technologies,	
USA)	 was	 used	 as	 the	 MS/TOF	 calibrant.	 Water	 for	 HPLC	
studies	 was	 obtained	 from	 ultrapure	 water	 purification	 unit	
(Elga,	Wycombe,	England).	
	
2.2.	Apparatus	and	equipment	
	
Precision	 water	 baths	 (Julabo,	 Seelbach,	 Germany)	 were	
used	for	hydrolytic	studies.	Thermal	stress	testing	was	carried	
out	 using	 a	 dri	 bath	 ((Thermolyne,	 Iowa,	 USA).	 The	
photostability	 chamber	 (KBWF	 240,	 WTC	 Binder,	 Tuttlingen,	
Germany)	 was	 equipped	 with	 an	 illumination	 bank	 on	 the	
inside	top,	consisting	of	a	combination	of	two	UV	(OSRAM	L18	
W/73)	and	four	white	fluorescent	(PHILIPS	TRULITE	18W/86)	
lamps,	 in	 accordance	with	 Option	 2	 of	 the	 ICH	 guideline	 Q1B	
[14].	 Both	 fluorescent	 and	 UV	 lamps	 were	 put	 on	
simultaneously.	 The	 samples	 were	 placed	 at	 a	 distance	 of	 9	
inches	 from	 the	 light	 bank.	 A	 lux	 meter	 (model	 ELM	 201,	
Escorp,	 New	 Delhi,	 India)	 and	 a	 UV	 radiometer	 (model	 206,	
PRC	 Krochmann	 GmbH,	 Berlin,	 Germany)	 were	 used	 to	
measure	visible	illumination	and	UV	energy,	respectively.	Other	
equipments	used	for	the	study	were	sonicator	(3210,	Branson	
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Ultrasoincs	Corporation,	CT,	USA),	precision	analytical	balance	
(AG	135,	Mettler	Toledo,	Schwerzenbach,	Switzerland),	pH/Ion	
analyzer	 (MA	 235,	 Mettler	 Toledo,	 Schwerzenbach,	
Switzerland)	 and	 autopipettes	 (Eppendorf,	 Hamburg,	
Germany).	
The	stand‐alone	HPLC	system	was	VP	series	from	Shimadzu	
(Kyoto,	 Japan)	 and	 was	 equipped	 with	 a	 photodiode	 array	
detector.	 It	 was	 controlled	 by	 SP1	 software	 ver.	 6.14.	 LC‐
MS/TOF	results	were	obtained	on	a	system	in	which	LC	(model	
1100,	 Agilent	 Technologies,	 Waldbronn,	 Germany)	 was	
hyphenated	 to	 MicrOTOF‐Q	 spectrometer	 (Bruker	 Daltonik,	
Bremen,	 Germany)	 using	 Hyphenation	 Star	 (version	 3.1)	 and	
MicrOTOF	 Control	 (version	 2.0)	 software.	 Multi‐stage	 mass	
(MSn)	 studies	were	 carried	 out	 on	 a	 LTQ	 XL	MS	 2.5.0	 system	
(Thermo,	San	Jose,	USA).	The	same	was	controlled	by	Xcalibur	
(version	2.0.7	SP1)	software.	The	MicrOTOF‐Q	instrument	was	
also	 used	 for	H/D	 exchange	 study	 on	 the	 drug,	while	 LTQ	 XL	
system	was	employed	for	on‐line	H/D	exchange	investigations	
on	the	product.	LC‐NMR	measurements	were	done	using	JNM‐
ECA	 500	 MHz	 spectrometer	 (JEOL,	 Tokyo,	 Japan)	 coupled	 to	
Prominence	LC	system	(Shimadzu,	Kyoto,	Japan)	and	controlled	
by	Delta	(Version	4.3)	and	LC‐NMR	Dio	(Version	2.0)	software,	
respectively.		
	
2.3.	Stress	testing	
	
The	 stressors,	 choice	 of	 their	 concentration	 and	
preparation	of	samples	were	based	on	our	previous	publication	
[15].	As	 the	drug	was	 insoluble	 in	water,	 it	was	dissolved	 in	a	
mixture	of	ACN	and	water	in	a	ratio	of	50:50	(v:v)	to	achieve	a	
stock	concentration	of	2	mg/mL.	This	stock	was	diluted	50:50	
(v:v)	 with	 the	 stressor	 (e.g.,	 HCl,	 water,	 NaOH	 or	 H2O2).	
Hydrolytic	 decomposition	 of	 the	 drug	was	 carried	 out	 in	 1	 N	
HCl,	water	and	1	N	NaOH	at	80	°C	for	48	h.	The	oxidative	study	
was	carried	out	in	15%	v/v	H2O2	at	room	temperature	for	2	d.	
Photolytic	studies	on	the	drug	in	the	solution	state	were	carried	
out	 in	0.1	N	HCl,	water	and	0.1	N	NaOH	by	exposing	the	same	
for	 13,	 13	 and	 4	 d,	 respectively,	 in	 a	 photostability	 chamber	
delivering	8500	lx	of	fluorescent	and	0.5	W/m2	of	UV	light	and	
set	at	40±1	°C/75±3%	RH.	Photolytic	studies	in	the	solid	state	
were	performed	for	13	d	by	exposing	a	thin	layer	of	the	drug	to	
light	 under	 the	 same	 conditions	 as	 in	 solution	 state.	 Parallel	
blank	sets	were	kept	in	the	dark	for	respective	time	points.	For	
thermal	 stress	 testing,	 the	 drug	was	 sealed	 in	 glass	 vials	 and	
placed	in	a	thermostatic	block	at	50	°C	for	21	d	to	see	the	effect	
of	heat	alone	on	 the	drug	molecule.	After	 subjecting	 to	 stress,	
samples	were	withdrawn	at	suitable	time	intervals	and	diluted	
four	folds	with	ACN	and	water	(50:50,	v:v)	before	injection	into	
HPLC.	
	
2.4.	HPLC	method	development	
	
The	 LC	 column	 used	 in	method	 development	was	 Pursuit	
XRs	C‐8	(250	mm	x	4.6	mm	i.d.,	particle	size	5	m)	from	Varian	
(CA,	 USA).	 The	 ratios	 of	 organic	 modifier	 (ACN)	 and	 buffer	
(potassium	 dihydrogen	 phosphate	 (0.01	 M;	 pH	 3.0))	 were	
varied	 in	 the	 mobile	 phase	 to	 separate	 the	 drug	 and	
degradation	product(s).	The	buffer	was	prepared	by	dissolving	
1.36	 g	 of	 anhydrous	 potassium	 dihydrogen	 phosphate	 in	 1L	
water	 and	 the	 pH	 was	 adjusted	 using	 phosphoric	 acid.	 The	
buffer	pH	was	fixed	as	3.0	considering	the	drug’s	pKa	values	of	
3.1	 and	4.3,	 calculated	using	ACD	 software.	 The	mobile	 phase	
components	 were	 filtered	 through	 0.45	 μm	 nylon	 filter	 and	
degassed	before	use.	The	 injection	volume	and	flow	rate	were	
10	μL	and	1.0	ml/min,	respectively.	All	studies	were	carried	out	
at	25	oC.	The	wavelength	of	detection	was	233	nm.	
	
2.5.	MS/TOF,	MSn	and	H/D	exchange	studies	on	the	drug	
	
MS/TOF	 studies	 were	 performed	 in	 ESI	 positive	 mode	 in	
the	mass	range	of	50	to	1500	Da.	The	drug	was	also	subjected	
to	MSn	study,	wherein	fragmentation	of	various	precursor	ions	
was	 achieved	 using	 different	 collision	 energies.	 Mass	 system	
parameters	 were	 optimized	 appropriately	 for	 the	 above	
studies.	H/D	exchange	was	carried	out	on	the	MS/TOF	system	
by	direct	 injection	of	a	drug	solution	(2	ppm)	in	ACN	and	D2O	
(50:50,	v:v).	
	
2.6.	LC‐MS/TOF	and	on‐line	H/D	exchange	studies	on	the	
product	
	
The	drug	 and	 the	 stressed	 samples	were	 subjected	 to	 LC‐
MS/TOF	 studies	 using	 the	 developed	 LC	 method,	 but	 after	
replacing	 phosphate	 buffer	 with	 ammonium	 acetate	 having	
same	molarity	and	pH.	For	 internal	 calibration,	 the	ES	Tuning	
Mix	 solution	 was	 injected	 through	 a	 diverter	 in	 a	 specific	
segment	 near	 the	 peak	 of	 interest.	 The	 on‐line	H/D	 exchange	
mass	studies	were	carried	out	on	the	LTQ‐MSn	system,	wherein	
injection	of	D2O	was	made	via	an	additional	channel,	just	before	
the	peak	of	 interest	started	eluting	from	the	column.	The	flow	
of	D2O	was	continued	until	the	peak	was	completely	eluted.	
	
2.7.	LC‐NMR	studies	on	the	drug	and	the	product	
	
For	 LC‐NMR	 studies,	 the	 photolytic	 stressed	 sample	 was	
subjected	to	LC	using	the	same	mobile	phase	as	used	for	HPLC,	
but	 using	 D2O	 instead	 of	 water.	 The	 separated	 product	 was	
collected	 in	 the	 fraction	 loop	 using	 terminal	 cube	 and	 sent	 to	
inverse	3	mm	NMR	flow	probe	equipped	with	1H	{13C}	channels	
with	 pulsed‐field	 gradient	 along	 z‐axis.	 The	 active	 sample	
volume	of	the	probe	was	approximately	60	μl	and	the	transfer	
time	from	UV	cell	to	the	active	volume	was	45	s	at	a	flow‐rate	of	
0.5	mL/min.	One	dimensional	 1H	spectra	were	recorded	using	
the	WET	pulse	 sequences	 for	 solvent	 suppression	of	ACN	and	
residual	HOD	signal,	with	attenuated	power	at	64.5	[dB],	which	
gave	digital	resolution	of	0.76	Hz	per	point	for	the	product.	The	
spectra	were	 acquired	with	16	KHz	 spectral	width,	 16	K	data	
points	 and	 1024	 scans.	 The	 drug	 solution	 (4	 mg/mL)	 was	
prepared	in	the	mobile	phase	and	directly	 injected	to	LC‐NMR	
probe.	 The	 COSY	 spectra	 of	 the	 drug	 and	 its	 product	 were	
acquired	using	WET	pulse	sequences	for	solvent	suppression.	A	
total	 of	 96	 scans	 were	 collected	 at	 256	 iterations	 in	 the	 F1	
dimension,	 using	 a	 spectral	 width	 of	 ~10	 KHz	 in	 both	
dimensions.	It	was	found	that	traces	of	methanol	were	present	
as	 an	 impurity	 in	 the	 mobile	 phase.	 Therefore,	 the	 chemical	
shifts	of	1H	signals	were	referenced	to	the	methoxy	signal	of	the	
residual	CH3OH	at	δ	3.30	ppm.	
	
3.	Results	and	discussion		
	
3.1.	HPLC	method		
	
All	 the	 stressed	 solutions	were	 initially	 analyzed	by	HPLC	
using	ACN	(A)	and	potassium	dihydrogen	phosphate	(B)	in	the	
following	 same	 gradient	 mode:	 Tmin/A:B;	 T0‐1/10:90;	 T60‐
70/90:10;	T75‐82/10:90.	Except,	frontal	hump	in	the	drug	peak	in	
alkali	 solution	 exposed	 to	 light,	 a	 sharp	 single	 drug	 peak	was	
observed	in	all	other	stressed	solutions.	This	indicated	that	the	
drug	was	stable	to	all	the	stress	conditions	except	photo	alkali.	
To	 separate	 the	 overlapping	 product	 in	 photo	 alkaline	
condition,	 the	method	was	 improved	 by	 varying	 the	 gradient.	
The	 desired	 resolution	 (Rs	 >	 1.5)	 was	 achieved	 between	 the	
degradation	 product	 and	 the	 drug	 by	 using	 the	 gradient:	
Tmin/A:B;	 T0‐4/18:82;	 T18/29:71;	 T22/30:70;	 T25/18:82.	 The	
chromatogram	in	Figure	1	depicts	 the	separation	between	the	
two	components.	During	the	course	of	studies,	it	was	found	that	
the	 degradation	 product	 was	 stable	 during	 sample	 handling	
and	subsequent	analysis.	
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Figure	 1.	 HPLC	 chromatogram	 showing	 separation	 of	 the	 drug	 and	 the	
product.	
	
3.2.	Optimized	mass	parameters	
	
To	get	an	optimal	mass	spectrum,	the	selected	parameters	
for	 MS/TOF	 system	 were:	 end	 plate	 offset,	 ‐500	 V;	 capillary	
voltage,	‐4500	V;	nebuliser	gas	pressure,	1.2	Bar;	dry	gas	flow,	
6.0	 L/min;	 dry	 temperature,	 200	 °C;	 funnel	 1	 RF,	 150	 Vpp;	
funnel	2	RF,	300	Vpp;	 ISCID	energy,	0.0	 eV;	hexapole	RF,	120	
Vpp;	 quadrupole	 ion	 energy,	 4.0	 eV/Z;	 collision	 energy,	 22.0	
eV/z;	transfer	time,	50	µs;	collision	RF,	200	Vpp,	and	pre‐pulse	
storage,	10	µs.	Similarly,	the	tuned	parameters	for	MSn	system	
were:	 capillary	 temperature,	 300	 °C;	 capillary	 voltage,	 30	 V;	
tube	lens,	90	V;	spray	voltage,	5.0	kV,	and	sheath	gas	flow	rate,	
30	arb.	
	
3.3.	Mass	fragmentation	of	the	drug	
	
MS/TOF	spectrum	of	the	drug	showed	sixteen	fragments	in	
total	(Figure	2a;	labelled	a	to	p).	Their	accurate	mass,	possible	
molecular	 formula,	 exact	 theoretical	mass,	 error	 in	mmu,	 ring	
plus	 double	 bond	 (RDB)	 value	 and	 the	 number	 of	 labile	
hydrogen(s)	determined	from	H/D	exchange	studies	are	given	
in	 Table	 1.	 The	 MSn	 data	 are	 listed	 in	 Table	 2.	 These	 were	
employed	 to	establish	 fragmentation	pathway	 for	 the	drug,	 as	
shown	in	Figure	3.	Based	on	the	possibilities	of	protonation	in	
the	 drug	 structure,	 four	 routes	 were	 assigned	 for	 its	
fragmentation.	The	first	two	were	inter‐related,	and	proceeded	
with	subsequent	 losses	of	H2O	or	CO	to	generate	 fragments	of	
m/z	407,	m/z	389,	m/z	379	and	m/z	361.	The	third	and	major	
route	was	initiated	by	the	loss	of	thiophene,	yielding	a	fragment	
of	m/z	 341	 that	was	 further	 reduced	 to	 ions	 of	m/z	 297	 and	
m/z	207	 through	neutral	 loss	of	CO2	and	C8H6O2,	 respectively.	
Both	 these	 ions	 further	 produced	 a	 fragment	 of	m/z	 163	 by	
respective	neutral	 losses	of	C8H6O2	and	CO2.	The	 fourth	 route,	
which	involved	protonation	of	imidazole	ring,	cleaved	the	drug	
into	two	major	fragments	of	m/z	291	and	m/z	135	and	a	minor	
of	m/z	 290.	The	 ion	of	m/z	 291	 first	 lost	H2O	 and	 then	CO	 to	
yield	 daughters	 of	 m/z	 273	 and	 m/z	 245,	 respectively.	 The	
pathway	m/z	290		m/z	272		m/z	244	 involved	 loss	of	 the	
substituted	 phenyl	 moiety	 without	 hydrogen	 transfer	 to	 the	
imidazole	 ring,	 which	 could	 only	 be	 justified	 through	 the	
formation	of	radical	cations.	
	
3.4.	LC‐MS/TOF	and	on‐line	H/D	exchange	studies	
	
LC‐MS/TOF	studies	on	the	drug	(Figure	2a)	and	its	product	
(Figure	2b)	showed	the	latter	to	have	the	same	mass	profile	as	
that	 of	 the	 drug.	 The	 calculated	 chemical	 formula	 for	 each	
fragment	 (Table	 1)	 was	 also	 same	 for	 the	 both.	 Even	 on‐line	
H/D	exchange	studies	showed	the	same	molecular	mass	of	m/z	
428	 for	 the	 drug	 and	 the	 product,	 indicating	 same	number	 of	
the	 labile	 hydrogens.	 The	 only	 difference	 was	 in	 relative	
fragment	 ion	 intensities	 in	MS/TOF	 spectra	 (Figure	 2),	which	
was	seen	even	on	repeated	injections.	While	the	ion	of	m/z	207	
(53.1%)	was	most	prominent	in	case	of	the	drug,	the	same	was	
very	low	abundant	(3.1%)	in	the	degradation	product.	A	similar	
situation	 existed	 for	 the	 fragment	 of	 m/z	 341.	 Conversely,	
abundance	 of	 the	 fragment	 of	 m/z	 273	 was	 higher	 in	 the	
product	(43.5%)	than	the	corresponding	ion	in	case	of	the	drug	
(6.8%).	
	
	
	(a)	
	
	
	(b)	
	
Figure	 2. LC‐MS/TOF	 spectrum	 of	 the	 drug	 (a)	 and	 the	 product	 (b);	 The	
labels	a‐p	are	for	different	fragments	of	the	drug.	The	same	apply	even	to	the	
fragments	for	the	product	in	lower	figure	b.	
		
3.5.	LC‐NMR	study	
	
1H	LC‐NMR	spectra	of	the	drug	and	the	product	are	shown	
in	Figure	4.	The	corresponding	1H	peak	assignments	along	with	
multiplicity	and	coupling	constants,	and	COSY	correlations	are	
given	in	Table	3.	The	prominent	peaks	for	the	drug	included:	(i)	
two	 doublets	 at	 δ	 7.95	 and	 δ	 7.16	 ppm	 arising	 due	 to	 two	
aromatic	resonances	corresponding	to	the	positions	H‐9,11	and	
H‐8,12,	respectively;	(ii)	two	singlets	arising	from	H‐5	and	H‐13	
at	 δ	 7.58	 and	 δ	 7.35	 ppm,	 respectively;	 (iii)	 three	 aromatic	
resonances	 (two	 doublets,	 one	 multiplet)	 arising	 due	 to	
thiophene	ring	corresponding	to	H‐18,	H‐20	and	H‐19	at	δ	7.22,	
δ	 6.65	 and	 δ	 6.90	 ppm,	 respectively;	 (iv)	 two	 singlets	
corresponding	to	methylene	protons	for	position	H‐6	and	H‐15	
at	 δ	 5.50	 and	 δ	 3.96	 ppm,	 respectively,	 and	 (v)	 two	 triplets	
corresponding	 to	 methyl	 and	 methylene	 protons	 arising	 at	 δ	
0.78	 and	 δ	 2.97	 ppm	 for	 H‐4’	 and	H‐1’,	 respectively,	 and	 two	
multiplets	 arising	 at	 δ	 1.26	 and	 δ	 1.55	 ppm	 (H‐3’	 and	 H‐2’)	
representing	the	methylene	protons	of	the	butyl	chain.	Further	
COSY	data	(Table	3)	also	supported	the	peak	assignments.	The	
1H	 LC‐NMR	 of	 the	 product	 showed	 only	 one	major	 dissimilar	
peak	 (δ	5.57	ppm)	when	 compared	 to	 the	drug	 (δ	7.35	ppm).	
Other	 1H	 peaks	 were	 insignificantly	 changed,	 while	 COSY	
correlations	were	the	same	to	the	drug	(Table	3).	
	
3.6.	Structure	elucidation	
	
As	 discussed	 above,	 identical	 molecular	 ion	 mass	 and	
similar	fragmentation	profile	 in	LC‐MS	study	revealed	that	the	
product	was	an	 isomer	of	 the	drug.	This	was	verified	 through	
distinguishing	spectral	difference	in	LC‐NMR	spectra.	
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Figure	3.	Proposed	mass	fragmentation	pattern	of	the	drug.	The	value	of	calculated	accurate	mass	is	shown	below	each	structure,	along	with	the	mass	obtained	
in	H/D	exchange	study	(in	brackets).	
	
	
The	 observed	 upfield	 behaviour	 of	 H‐13	 in	 the	 product,	
(Table	 3)	 indicated	 that	 the	 surroundings	 of	 vinyl	 H‐13	 had	
changed	 significantly.	 This	 was	 only	 possible	 if	 the	 drug	 (E	
form)	 was	 converted	 to	 Z	 isomer.	 Due	 to	 this	 geometric	
isomerization,	 d‐orbital	 electrons	 of	 sulfur	 showed	 shielding	
effect	 to	 vinyl	 H‐13.	 Moreover,	 observed	 minor	 change	 in	 J	
value	 of	 H‐18	 might	 be	 due	 this	 spatial	 non‐bonding	
interaction.	 The	 supposition	 of	 isomerization	 was	 verified	
through	 correlation	 of	 the	 observed	 differential	 MS	 peak	
intensities	 of	 the	 drug	 and	 the	 product	 (Figure	 2a	 and	 2b),	
considering	that	isomers	are	known	to	show	different	fragment	
ion	intensities	[16,17].		
As	discussed	under	Section	3.4,	the	intensity	of	mass	peaks	
of	m/z	 207	and	m/z	 341	were	 significantly	 less	 in	 case	of	 the	
product.	 This	 was	 perhaps	 due	 to	 hindered	 protonation	 of	
thiophene	 ring	 system	 by	 spatial	 non‐bonding	 interaction	 of	
sulphur	 and	 vinyl	 hydrogens.	 In	 this	 circumstance,	
fragmentation	 from	 other	 site	 (route	 four;	 N3‐C6;	 Figure	 3)	
could	be	preferred,	and	this	phenomenon	was	clearly	seen	from	
the	 observed	 higher	 intensity	 of	 the	 ion	 of	m/z	 273	 for	 the	
product.	Incidentally,	a	similar	observation	was	made	by	Brum	
et	al.	in	MS	study	on	E	and	Z	isomers	of	eprosartan	carried	out	
in	 APCI	 mode	 through	 direct	 injection	 [18].	 This	 further	
strengthens	 the	 identity	 of	 degradation	 product	 formed	 in	
photo	alkali	condition	as	discussed	above.	
The	 elucidated	 structure	 is	 further	 supported	 by	 the	
mechanism	 of	 isomerization,	 outlined	 in	 Figure	 5.	 It	 is	
postulated	that	eprosartan	(E‐isomer)	is	converted	to	Z‐isomer	
under	 photo	 alkali	 condition	 through	 ionization	 of	 carboxyl	
group,	which	stabilizes	the	radical	formed	during	the	transition	
state.	 The	 geometrical	 conversion	 (cis	 to	 trans)	 of	 vinyl	
compounds	on	exposure	to	light	is	known	previously	[19,20].	
	
4.	Conclusion	
	
This	 systematic	 stress	 degradation	 study	 on	 eprosartan,	
carried	out	according	to	ICH/WHO	guidelines,	reveals	that	the	
drug	is	stable	to	hydrolysis,	oxidation,	thermal	stress	and	even	
to	light	in	solid	state	and	in	neutral	and	acid	solutions.	It	is	only	
unstable	 in	photo	 alkaline	 solutions.	 The	degradation	product	
is	characterized	through	complementary	use	of	hyphenated	LC‐
MS	and	LC‐NMR	techniques	as	Z‐isomer	of	the	drug	((Z)‐4‐((2‐
butyl‐5‐(2‐carboxy‐3‐(thiophen‐2‐yl)prop‐1‐enyl)‐1H‐		
	
156	 Shah	et	al.	/	European	Journal	of	Chemistry	2	(2)	(2011)	152‐157	
 
Table	1.	MS/TOF	data	and	relative	ion	intensities	of	the	drug	and	the	product	along	with	MSn	and	on‐line	H/D	exchange	data	for	the	drug.		
Peak	
no.	
MS/TOF	data	and	
relative	ion	
intensity	of	drug	
(of	product)	
Best	
possible	
molecular	
formula		
Exact	mass	
of	most	
probable	
structure	
Error	in	
mmu	for	
drug	(for	
product)	
RDB Possible	
parent	
fragment	
Difference	
from	
parent	
ion	
Molecular	formulae	for	
the	best	two	possible	
losses	
Mass	values	
after	H/D		
exchange		
Number	of	
labile	
hydrogens	
Loss	1 Loss	2	
[M+H]+	 425.1534;		
100	(425.1540;	100)	
C23H25N2O4S		 425.1530	 0.4	(1.0) 12.5 ‐ 428	 3
a	 407.1425;		
8.8	(407.1432;	23.2)	
C23H23N2O3S	 407.1424	 0.1	(0.8) 13.5 [M+H]+ 18.0106 H2O 408	 1
b		 389.1314;		
1.2	(389.1322;	1.0)	
C23H21N2O2S		 389.1318	 ‐0.4	(0.4) 14.5 a 18.0106 H2O 389	 0
c		 379.1473;		
5.0	(379.1478;	9.5)	
C22H23N2O2S	 379.1475	 ‐0.2	(0.3) 12.5 a 27.9951 CO N2	 380	 1
d	 361.1371;		
1.0	(361.1373;	0.8)	
C22H21N2OS	 361.1369	 0.2	(0.4) 13.5 b 27.9951 CO N2	 361	 0
e		 341.1489;		
20.7	(341.1491;	0.7)	
C19H21N2O4		 341.1496	 ‐0.7	(‐0.5) 10.5 [M+H]+ 84.0038 C4H4S C3H2NO2	 343	 2
f		 297.1583;		
2.7	(297.1532;	0.2)	
C18H21N2O2		 297.1598	 ‐1.4	(‐6.5) 9.5 e 43.9904 CO2 N2O	 298	 1
g		 291.1144;		
2.2	(291.1141;	1.0)	
C15H19N2O2S		 291.1162	 ‐1.8	(‐2.0) 7.5 [M+H]+ 134.0379 C8H6O2 C5H10O2S	 294	 3
h		 290.1073;		
1.5	(290.1079;	1.2)	
C15H18N2O2S		 290.1083	 ‐1.0	(‐0.4) 8.0 [M+H]+ 135.0451 C8H7O2 C5H11O2S	 292	 2
I	 273.1036;		
6.8	(273.1050;	43.5)	
C15H17N2OS	 273.1056	 ‐2.0	(‐0.6) 8.5 g 18.0108 H2O 274	 1
J	 272.0967;		
7.9	(272.0972;	6.6)	
C15H16N2OS	 272.0978	 ‐1.1	(‐0.6) 9.0 h 18.0101 H2O 273	 1
k	 245.1101;		
4.6	(245.1112;	9.5)	
C14H17N2S 245.1107	 ‐0.6	(0.5) 7.5 i 27.9933 CO N2	 246	 1
l	 244.1033;		
2.7	(244.1034;	2.1)	
C14H16N2S 244.1029	 ‐0.4	(0.5) 8.0 j 27.9941 CO N2	 244	 0
m	 207.1142;		
53.1	(207.1145;	3.1)	
C11H15N2O2	 207.1128	 1.4	(1.7) 5.5 e 134.0333 C8H6O2 C3H6N2O4	 209	 2
n	 189.1026;		
1.2	(189.1036;	2.4)	
C11H13N2O 189.1022	 0.4	(1.4) 6.5 m 18.012 H2O 189	 0
o	 163.1234;		
9.8	(163.1209;	0.6)	
C10H15N2 163.1230	 ‐0.4	(‐2.1) 4.5 m 43.9915 CO2 N2O	 164	 1
p	 135.0437;		
14.9	(135.0436;	4.8)	
C8H7O2	 135.0441	 ‐0.3	(‐0.4) 5.5 [M+H]+ 290.1086 C15H18N2O2S C15H18N2O4	 136	 1
a‐h:	peak	numbers	shown	in	Figure	2a.	
	
	
Table	2.	MSn	fragmentation	of	the	drug.	
MSn	 Precursor	ion	 Product	ions
MS2	 425	 407,	379,	361,	341,	291,	290,	207,	135
MS3	 407	 389,	379,	361
341	 297,	207,	189,	163
291	 273,	245
290	 272,	244
MS4	 389	 361
297	 163
207	 189,	163
273	 245
	
	
Table	3.	1H	LC‐NMR	peak	assignments	of	the	drug	and	the	product	along	with	multiplicity,	coupling	constants	and	COSY	data.		
Position	
Drug	 Product
δH/ppm	(Multiplicity,	J	value	in	Hz)	 COSY	 δH/ppm	(Multiplicity,	J value	in	Hz)	 COSY	
5	 7.58	(s)	 ‐	 7.48	(s) ‐	
6	 5.50	(s)	 ‐	 5.34	(s) ‐	
8	 7.16	(d,	7.64)	 H‐9	 7.11	(d,	7.64) H‐9	
9	 7.95	(d,	7.64)	 H‐8	 7.96	(d,	7.64) H‐8	
11	 7.95	(d,	7.64)	 H‐12	 7.96	(d,	7.64) H‐12	
12	 7.16	(d,	7.64)	 H‐11	 7.11	(d,	7.64) H‐11	
13	 7.35	(s)	 ‐	 5.57	(s) ‐	
15	 3.96	(s)	 ‐	 3.79	(s) ‐	
18	 7.22	(d,	5.35)	 H‐19	 7.12	(d,	4.59) H‐19	
19	 6.90	(m)	 H‐18,	H‐20 6.90	(m) H‐18,	H‐20
20	 6.65	(d,	3.06)	 H‐19	 6.74	(d,	3.06) H‐19	
1’	 2.97	(t,	7.64)	 H‐2’	 2.94	(t,	7.64) H‐2’	
2’	 1.55	(m)	 H‐1’,	H‐3’ 1.57	(m) H‐1’,	H‐3’	
3’	 1.26	(m)	 H‐2’,	H‐4’ 1.28	(m) H‐2’,	H‐4’	
4’	 0.78	(t,	7.64)	 H‐3’	 0.80	(t,	7.64) H‐3’	
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Figure	4.	1H	LC‐NMR	spectra	of	the	drug	(upper)	and	the	product	(lower).
	
	
	
	
Figure	5.	Mechanism	of	formation	of	Z‐isomer	from	the	drug.
	
	
imidazol‐1‐yl)ethyl)benzoic	 acid).	 Though	 it	 is	 a	 reported	
photolytic	 product	 of	 eprosartan,	 the	 exact	 condition	 under	
which	it	is	formed	from	the	drug	under	light	is	identified	here.	
The	 mechanism	 of	 formation	 of	 the	 product	 is	 proposed.	 A	
complete	mass	 fragmentation	pathway	of	 the	drug	 is	reported	
for	 the	 first	 time.	 Also,	 extensive	MS	 and	NMR	data	 and	 their	
interpretation	 are	 provided	 for	 both	 the	 drug	 and	 the	
degradation	 product.	 The	 given	 information	 can	 be	 gainfully	
exploited	 in	 future	 investigations	 on	 characterization	 of	
process	related	impurities,	drug‐excipient	interaction	products,	
and/or	metabolites	of	 the	drug.	Overall,	 the	study	strengthens	
the	utility	of	hyphenated	tools	for	characterizing	the	unknown	
products	 formed	 in	 small	 quantities	 during	 stability	 or	 stress	
studies,	against	 the	use	of	cumbersome	procedure	of	 isolation	
or	synthesis.	
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